Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Connecticut Wealth Management LLC

Connecticut Wealth Management LLC raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 26.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,549 shares of the medical research company’s stock after buying an additional 2,589 shares during the quarter. Connecticut Wealth Management LLC’s holdings in Edwards Lifesciences were worth $957,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EW. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $34,000. Operose Advisors LLC grew its position in shares of Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares during the last quarter. SRS Capital Advisors Inc. grew its position in shares of Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after buying an additional 474 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $52,000. Finally, ORG Partners LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $66,000. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $84.77, for a total value of $2,487,999.50. Following the completion of the sale, the director now owns 4,486 shares in the company, valued at approximately $380,278.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the transaction, the director now owns 4,486 shares in the company, valued at approximately $380,278.22. The disclosure for this sale can be found here. Insiders sold a total of 237,749 shares of company stock worth $20,920,934 in the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Up 0.2 %

Shares of EW stock traded up $0.19 during trading hours on Friday, reaching $85.25. 2,327,197 shares of the stock traded hands, compared to its average volume of 3,001,614. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The business has a fifty day moving average price of $90.08 and a 200 day moving average price of $79.46. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $51.37 billion, a PE ratio of 36.75, a PEG ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Citigroup upped their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. Finally, Oppenheimer upped their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.